{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:46:53Z","timestamp":1767865613738,"version":"3.49.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,20]]},"DOI":"10.4103\/0366-6999.179783","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T08:47:07Z","timestamp":1460018827000},"page":"883-890","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders"],"prefix":"10.1097","volume":"129","author":[{"given":"Qiu-Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Shi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Mei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.fertnstert.2010.09.032","article-title":"Polycystic ovary syndrome: An ancient disorder?","volume":"95","author":"Azziz","year":"2011","journal-title":"Fertil Steril"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/09513590.2010.488776","article-title":"Obesity and insulin resistance in women with polycystic ovary syndrome","volume":"27","author":"Chun-Sen","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.fertnstert.2008.09.003","article-title":"Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women","volume":"92","author":"Liou","year":"2009","journal-title":"Fertil Steril"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.fertnstert.2005.10.054","article-title":"Obesity and androgens: Facts and perspectives","volume":"85","author":"Pasquali","year":"2006","journal-title":"Fertil Steril"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijgo.2010.01.014","article-title":"Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome","volume":"109","author":"El-Mazny","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.5694\/mja11.10915","article-title":"Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline","volume":"195","author":"Teede","year":"2011","journal-title":"Med J Aust"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-09-0733","article-title":"Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome","volume":"162","author":"Diamanti-Kandarakis","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-1-20210129","first-page":"714","article-title":"Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome","volume":"124","author":"Liao","year":"2011","journal-title":"Chin Med J"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis","volume":"21","author":"Naderpoor","year":"2015","journal-title":"Hum Reprod Update"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/humupd\/dmi005","article-title":"Combined oral contraceptives in the treatment of polycystic ovary syndrome","volume":"11","author":"Vrb\u00edkov\u00e1","year":"2005","journal-title":"Hum Reprod Update"},{"key":"R13-1-20210129","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study","volume":"85","author":"Morin-Papunen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/humrep\/del407","article-title":"Polycystic ovary syndrome, oral contraceptives and metabolic issues: New perspectives and a unifying hypothesis","volume":"22","author":"Nader","year":"2007","journal-title":"Hum Reprod"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2002-020997","article-title":"Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study","volume":"88","author":"Morin-Papunen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1210\/jc.2003-030328","article-title":"Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel","volume":"88","author":"Cagnacci","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/jc.2007-0282","article-title":"Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome","volume":"92","author":"Luque-Ram\u00edrez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/09513590802217027","article-title":"Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome","volume":"24","author":"Wu","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","article-title":"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: A randomized controlled study","volume":"17","author":"Elter","year":"2002","journal-title":"Hum Reprod"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1210\/jc.2014-1135","article-title":"Body composition is improved during 12 months\u2019 treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome","volume":"99","author":"Glintborg","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: A short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13625180600983082","article-title":"Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome","volume":"12","author":"Pehlivanov","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2003-031158","article-title":"Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study","volume":"89","author":"Guido","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.fertnstert.2009.10.016","article-title":"Comparison of effects of 3 mg drospirenone plus 20 mg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome","volume":"94","author":"Fruzzetti","year":"2010","journal-title":"Fertil Steril"},{"key":"R26-1-20210129","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-12-9","article-title":"Ethinylestradiol30mg-drospirenone and metformin: Could this combination improve endothelial dysfunction in polycystic ovary syndrome?","volume":"12","author":"Ilie","year":"2012","journal-title":"BMC Endocr Disord"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.12659\/MSM.894926","article-title":"Evaluation of apelin and insulin resistance in patients with PCOS and therapeutic effect of drospirenone-ethinylestradiol plus metformin","volume":"21","author":"Sun","year":"2015","journal-title":"Med Sci Monit"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/humupd\/dmp024","article-title":"Visually scoring hirsutism","volume":"16","author":"Yildiz","year":"2010","journal-title":"Hum Reprod Update"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1365-4362.1997.00099.x","article-title":"A comparison of current acne grading systems and proposal of a novel system","volume":"36","author":"Doshi","year":"1997","journal-title":"Int J Dermatol"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/13625180400007751","article-title":"Ethinylestradiol\/cyproterone acetate in polycystic ovary syndrome: Lipid and carbohydrate changes","volume":"9","author":"Villaseca","year":"2004","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/09513599009009803","article-title":"Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome","volume":"4","author":"Prelevic","year":"1990","journal-title":"Gynecol Endocrinol"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/09637480601137066","article-title":"Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism","volume":"23","author":"Batukan","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.fertnstert.2005.07.1306","article-title":"Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome","volume":"85","author":"Mastorakos","year":"2006","journal-title":"Fertil Steril"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/humrep\/deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: A systematic review and meta-analysis of observational studies","volume":"26","author":"Halperin","year":"2011","journal-title":"Hum Reprod"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00404-014-3217-5","article-title":"Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: A randomized clinical trial","volume":"290","author":"Kahraman","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1447-0756.2011.01682.x","article-title":"Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome","volume":"38","author":"Bhattacharya","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","article-title":"Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome","volume":"98","author":"Bhattacharya","year":"2012","journal-title":"Fertil Steril"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer","year":"2007","journal-title":"Diabetes Care"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.179783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:38:43Z","timestamp":1623958723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201604200-00001"}},"subtitle":["A Prospective Randomized Control Trial"],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.179783","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}